NASDAQ:GRI GRI Bio (GRI) Stock Price, News & Analysis $4.37 -1.50 (-25.55%) As of 03/28/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GRI Bio Stock (NASDAQ:GRI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GRI Bio alerts:Sign Up Key Stats Today's Range$4.32▼$6.0650-Day Range$4.37▼$12.2552-Week Range$4.32▼$172.49Volume60,449 shsAverage Volume16,027 shsMarket Capitalization$2.29 millionP/E RatioN/ADividend YieldN/APrice Target$195.50Consensus RatingBuy Company OverviewGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Read More… Remove Ads GRI Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreGRI MarketRank™: GRI Bio scored higher than 64% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGRI Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGRI Bio has received no research coverage in the past 90 days.Read more about GRI Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GRI Bio are expected to grow in the coming year, from ($3.04) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GRI Bio is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GRI Bio is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGRI Bio has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about GRI Bio's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.69% of the float of GRI Bio has been sold short.Short Interest Ratio / Days to CoverGRI Bio has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GRI Bio has recently decreased by 29.20%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldGRI Bio does not currently pay a dividend.Dividend GrowthGRI Bio does not have a long track record of dividend growth.Read more about GRI Bio's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.69% of the float of GRI Bio has been sold short.Short Interest Ratio / Days to CoverGRI Bio has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GRI Bio has recently decreased by 29.20%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.03 News SentimentGRI Bio has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for GRI Bio this week, compared to 1 article on an average week.MarketBeat Follows1 people have added GRI Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GRI Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.13% of the stock of GRI Bio is held by insiders.Percentage Held by InstitutionsOnly 33.95% of the stock of GRI Bio is held by institutions.Read more about GRI Bio's insider trading history. Receive GRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GRI Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GRI Stock News HeadlinesGRI Bio files to sell common stock, warrants, no amount givenMarch 26, 2025 | markets.businessinsider.comGRI Bio Participates in a Virtual Investor CEO Connect SegmentMarch 18, 2025 | globenewswire.comThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy shareholder value over time. Even as gold prices rise.March 31, 2025 | Golden Portfolio (Ad)GRI Bio expects cash to fund operations into Q2 of 2025March 18, 2025 | markets.businessinsider.comGRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)March 17, 2025 | globenewswire.comGRI Bio Back In Compliance With Nasdaq Minimum Bid RuleMarch 13, 2025 | nasdaq.comGRI Bio regains compliance with Nasdaq minimum bid price ruleMarch 11, 2025 | markets.businessinsider.comGRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price RuleMarch 11, 2025 | markets.businessinsider.comSee More Headlines GRI Stock Analysis - Frequently Asked Questions How have GRI shares performed this year? GRI Bio's stock was trading at $14.0828 at the beginning of the year. Since then, GRI stock has decreased by 69.0% and is now trading at $4.37. View the best growth stocks for 2025 here. When did GRI Bio's stock split? GRI Bio shares reverse split before market open on Monday, February 24th 2025. The 1-17 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. Who are GRI Bio's major shareholders? GRI Bio's top institutional investors include Geode Capital Management LLC (0.85%) and Virtu Financial LLC (0.34%). How do I buy shares of GRI Bio? Shares of GRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GRI Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that GRI Bio investors own include SoFi Technologies (SOFI), NuCana (NCNA), Caribou Biosciences (CRBU), Cardio Diagnostics (CDIO), Intrusion (INTZ), Lonestar Resources US (LONE) and Children's Place (PLCE). Company Calendar Today3/31/2025Next Earnings (Estimated)5/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GRI CIK1824293 Webwww.vallon-pharma.com Phone267-607-8255FaxN/AEmployees1Year FoundedN/APrice Target and Rating Average Stock Price Target$195.50 High Stock Price Target$221.00 Low Stock Price Target$170.00 Potential Upside/Downside+4,373.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($11.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-289.05% Return on Assets-165.01% Debt Debt-to-Equity RatioN/A Current Ratio3.10 Quick Ratio3.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.22 per share Price / Book0.84Miscellaneous Outstanding Shares525,000Free Float8,921,000Market Cap$2.29 million OptionableNot Optionable Beta-2.10 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:GRI) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.